共 50 条
Regulatory-grade clinical trial design using real-world data
被引:14
|作者:
Levenson, Mark S.
[1
]
机构:
[1] US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
关键词:
Evidence;
bias;
heterogeneity;
real-world;
D O I:
10.1177/1740774520905576
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.
引用
收藏
页码:377 / 382
页数:6
相关论文